Shield Therapeutics PLC Total Voting Rights update (6411U)

TIDMSTX

RNS Number : 6411U

Shield Therapeutics PLC

31 July 2020

Shield Therapeutics plc

("Shield" or the "Group")

Total Voting Rights Update

London, UK, 31 July 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer (R) (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 117,188,657 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

 
 Shield Therapeutics plc                             www.shieldtherapeutics.com 
 Tim Watts, Chief Executive 
  Officer                                                   [phone] 
 Lucy Bailey, General Counsel 
  and Company Secretary                                    [phone] 
 
 
   Nominated Advisor and Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                    [phone] 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                     [phone] 
 
 Financial PR & IR Advisor 
 Walbrook PR                       [phone] or [e-mail] 
                                          [phone] / [phone] 
 Paul McManus/Lianne Cawthorne                                              303 
 

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TVRFBLFXBDLFBBZ

(END) Dow Jones Newswires

July 31, 2020 02:00 ET (06:00 GMT)